New drug cocktail aims to shrink Hard-to-Treat breast tumors
NCT ID NCT07153965
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial is testing a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer. The study will enroll 47 participants whose cancer has already been treated but has spread or come back. The goal is to see if the combination can shrink tumors and slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (Sac-TMT) and tagitanlimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced triple negative breast cancer that has not responded to prior therapy.
- What could go wrong
- This is an early Phase 2 study with only 47 participants, so results may not apply to all patients. The drugs can cause side effects, and the trial may not show enough benefit to move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 30000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a new drug combo outsmart triple-negative breast cancer?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?